BCL2 and neoplasm: Yang et al. treated HCT116 with apigenin in combination with 5-FU and showed that apigenin significantly increased the Bax/Bcl-2 ratio and upregulated the expression of p53 and ROS in HCT116 and HT29 cells, thereby inhibiting the formation and development of tumor cells.